BEY-2153
/ BeyondBio
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 20, 2025
A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease
(clinicaltrials.gov)
- P2 | N=90 | Not yet recruiting | Sponsor: BeyondBio Inc.
New P2 trial • Alzheimer's Disease • CNS Disorders
March 10, 2025
A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=88 | Completed | Sponsor: BeyondBio Inc. | Recruiting ➔ Completed
Trial completion • Alzheimer's Disease • CNS Disorders
November 30, 2020
A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants
(clinicaltrials.gov)
- P1; N=88; Recruiting; Sponsor: BeyondBio Inc.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Alzheimer's Disease • CNS Disorders
July 20, 2020
A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants
(clinicaltrials.gov)
- P1; N=88; Not yet recruiting; Sponsor: BeyondBio Inc.
Clinical • New P1 trial • Alzheimer's Disease • CNS Disorders
1 to 4
Of
4
Go to page
1